Efavirenz Metabolism and CNS Toxicity in Ugandan Children: CYP2B6 Genotype Impact

A 2015–2016 prospective study of 99 ART-naïve Ugandan children aged 3–12 years, quantifying efavirenz and its metabolites in plasma over 24 weeks. The dataset, authored by Sandra Soeria-Atmadja and shared under CC-BY-4.0, includes genotyping for CYP2B6 and CYP2A6 SNPs and assessment of central nervous system adverse effects. It represents the first study of efavirenz metabolites in a pediatric population.

Use Cases

• Modeling drug metabolism pathways based on quantified plasma levels of efavirenz and its hydroxy-metabolites.
• Investigating associations between CYP2B6 metabolizer phenotypes and central nervous system adverse effects.
• Studying autoinduction of efavirenz metabolism over time in extensive metabolizers.

Strengths

• Includes longitudinal plasma sampling at 2, 6, 12, and 24 weeks for 99 pediatric patients.
• Quantifies multiple metabolite forms, including unconjugated and conjugated 8-OH-EFV, 7-OH-EFV, and EFAdeg.
• Links clinical CNS symptom data with specific plasma concentration thresholds (e.g., >4,000 ng/mL).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is specific to a Ugandan pediatric cohort from 2015–2016, which may limit generalizability.

Provenance

Source

figshare

Collection Method

Prospective clinical study using liquid chromatography high-resolution tandem mass spectrometry and genotyping.

Time Range

2015–2016

Freshness

Last updated 2026-04-24 05:40:38; freshness should be verified.

Geography

Uganda